Amicus Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of
earliest event reported):
(Exact Name of Registrant as Specified in Its Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of Principal Executive Offices, and Zip Code)
Registrant’s Telephone Number, Including Area Code
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR §240.12b-2). Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.07 - Submission of Matters to a Vote of Security Holders.
At the 2025 Annual Meeting of Stockholders of the Company, held on June 5, 2025, the Company’s stockholders elected Michael A. Kelly, Margaret G. McGlynn, Michael G. Raab and Glenn P. Sblendorio as Class III directors to serve a three-year term expiring at the 2028 Annual Meeting of Stockholders and until their respective successors have been elected. In addition, the stockholders (i) approved the 2025 Equity Incentive Plan, (ii) ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, and (iii) approved, on an advisory basis, the compensation paid to the Company’s named executive officers. The final voting results on these matters were as follows:
| 1. | Election of Directors. |
| Nominee | Votes For | Votes Withheld | Broker Non-Votes | |||||||||
| Michael A. Kelly | 256,542,874 | 5,972,321 | 20,343,283 | |||||||||
| Margaret G. McGlynn | 253,119,576 | 9,395,619 | 20,343,283 | |||||||||
| Michael G. Raab | 159,986,932 | 102,528,263 | 20,343,283 | |||||||||
| Glenn P. Sblendorio | 255,741,822 | 6,773,373 | 20,343,283 | |||||||||
| 2. | Approval of the 2025 Equity Incentive Plan. |
| Votes For | Votes Against | Votes Abstain | Broker Non-Votes | |||||||||||
| 253,118,014 | 8,908,436 | 488,745 | 20,343,283 | |||||||||||
| 3. | Ratification of Ernst & Young LLC as the Company's Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2025. |
| Votes For | Votes Against | Votes Abstain | Broker Non-Votes | |||||||||||
| 277,786,618 | 5,006,701 | 65,159 | - | |||||||||||
| 4. | Approval, on an advisory basis, of the Company's executive compensation. |
| Votes For | Votes Against | Votes Abstain | Broker Non-Votes | |||||||||||
| 255,789,585 | 6,169,769 | 555,841 | 20,343,283 | |||||||||||
Item 9.01 Financial Statements and Exhibits
(d) Exhibits:
| Exhibit No. | Description |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
Signature Page
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AMICUS THERAPEUTICS, INC. | ||
| Date: June 5, 2025 | By: | /s/ Ellen S. Rosenberg |
| Name: | Ellen S. Rosenberg | |
| Title: | Chief Legal Officer and Corporate Secretary | |